Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Videos|July 29, 2013
Potential Cost Savings of Biosimilars
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
Advertisement
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
For more videos featuring Debbie Stern, please click on our
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
2
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
Understanding Kratom: Pharmacology, Safety, and Regulation
5